The research collaboration will be the first ever to focus on space-based drug formulation that could result in therapies for patients. May 13, 2026 -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity to develop improved formulations of treatments for rare pulmonary disease. Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of small molecule medicines for p

Rigel gets hands on Pfizer's recently-approved breast cancer drug Bayer cuts early-stage assets from pipeline Superior weight loss in Wegovy HD early responders 'First-of-its-kind' collab aims to incubate new biotechs Rigel gets hands on Pfizer's recently-approved breast cancer drug Having signalled their intent last year to find a US commercialisation partner for vepdegestrant, Pfizer and Arvinas reached an agreement with Rigel Pharmaceuticals on Tuesday to both market and further develop the

May 13, 2026 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Study of the Liver (EASL) Congress taking place May 27-30, 2026, in Barcelona, Spain. “We are pleased to present additional Phase 1a data on ABI-6250 at

May 12, 2026 -- Virginia Cancer Specialists announced today its participation as a leading clinical trial site in a landmark study evaluating daraxonrasib, a first‑in‑class targeted oral therapy for patients with previously treated, advanced KRAS‑mutated pancreatic cancer. Results from the Phase 1/2 trial, published recently in The New England Journal of Medicine, demonstrated exceptional disease control in a cancer historically resistant to targeted treatment. Positive Phase 3 results reported

May 12, 2026 -- Gelteq Limited (“Gelteq”) today announced that it has secured strategic debt financing of up to USD $3.5 million to accelerate its commercialization, expand clinical trial activity and execute on existing revenue opportunities. Gelteq intends to use the proceeds of the financing to advance its key strategic initiatives, including scaling up clinical trial programs as Gelteq advances its pharmaceutical products through regulatory pathways and ramping up commercialization of its

First Targeted Therapy Approved for NRG1+ Cholangiocarcinoma BIZENGRI Now Approved for Patients Harboring NRG1 Gene Fusions in Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, and Cholangiocarcinoma May 11, 2026 -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI® (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or metastatic cholangiocarci

Drug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to become the first to start a clinical trial of the potentially permanent approach. Fractyl Health has received clearance from European regulators to begin testing its gene therapy in the Netherlands, the company told Endpoints News. The treatment should allow people with type 2 diabetes to make more GLP-1 p

While regulatory reviews are under way in the US, EU and Japan, it is China that is seen as a key market if GSK is to achieve sales targets for its hepatitis B therapy bepirovirsen. And in an effort to realise these ambitions, the UK drugmaker on Monday announced a deal with Sino Biopharmaceutical and its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ). "By combining GSK's innovation with CTTQ's extensive local scale and execution, we want to reach more patients, deliver greater impact, and

May 11, 2026 -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the results of its PST-611 Phase 1 clinical trial (PST-611-CT1), in patients with late-stage dry Age-related Macular Degeneration (AMD) called Geographic Atrophy (GA), in a podium presentation at the ARVO 2026 Annual Meeting. GA is a multifactorial disease involving a dysregulation of iron

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms. In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo. Builds toward the establishment